

Impact Report 2025



About RegMed XB

RegMed XB is a translational research and valorisation platform that brings together academic, industrial, governmental and health foundation partners in the Netherlands and Flanders to advance the field of regenerative medicine.



For patients

Affordable regenerative medicine solutions for chronic diseases.



For society

A competitive and sustainable regenerative medicine industry.



COLLABORATION ACROSS THE ENTIRE ECOSYSTEM

Patients • Researchers • Clinicians • Industry • Investors • Regulators • Society



Utrecht



Leuven



Maastricht

Expanding the Ecosystem in 2025

Thematic Tech Transfer (TTT) programme



First.

BGV.


Diabetes Fonds

Hersen STICHTING



*7 Dutch Collaboration

In Life Sciences & Health with National Growth Fund (Nationaal Groeifonds) initiatives.



HOLOmicrobiome



health RI
enabling data driven health & life sciences



Strengthening the Flemish-Dutch Advanced Therapy Medicinal Products (ATMPs) ecosystem

Interreg
Vlaanderen-Nederland

Gefinancierd door
de Europese Unie

ATMP XB

Public-Private Partnerships (PPP)

HealthHolland

Diabetes Moonshot INSPIRE Project:

Diabetes Fonds



Maastricht University

Leiden University Medical Center



veldlaser



COMATE
Engineering & Design



Osteoarthritis Moonshot SPARC Project:

Leiden University Medical Center

TU/e Eindhoven University of Technology



Maastricht University

NecstGen
a non-profit CDMO



ReGEN Biomedical



Rousselot
by Darling Ingredients



Ecosystem Highlights



Flanders

- New Leuven workspace
- ATMP XB collaboration



RegMed XB's Annual Conference

- 200 attendees
- 25+ SME exhibitors
- First cross-border edition in Flanders



Policy Engagement

- With national innovation partners
- Joint response on ATMP legislation



Dutch Collaboration

- With seven National Growth Fund initiatives:
 - Biotech Booster
 - Health-RI
 - Holomicrobiome
 - NXTGEN
 - Ombion
 - Oncode Accelerator
 - PharmaNL



This project is supported by the
National Growth fund



Thematic Technology Transfer (TTT) programme and First Fund

- 2025-2030 programme €10 million awarded.
- 2020-2025 programme concluded.
 - 42 vouchers awarded
 - 13 start-ups supported
 - 7 investments completed
 - €5.47 million committed
 - >70% from TTT pipeline
 - Portfolio companies raised €61.6 million third-party funding (31-12-'25)



Netherlands Enterprise Agency

First.



Public-Private Partnerships (PPP)

€2 million allocated in 2025 for two Moonshot projects:

- Diabetes Moonshot (INSPIRE)
€1.02 million, with 10 partners, 3 years
- Osteoarthritis Moonshot (SPARC)
€0.98 million, with 11 partners, 2 years

Health/Holland

Moonshot Highlights



Cardiovascular

Donor heart kept evaluable for 24 hours

Perfusion conditions of the ex vivo heart bioreactor were optimized so a donor heart stays in evaluable condition for a consistent 24 hours, with 48 hours in reach.

Biomarker panel validated

Biomarkers of endothelial dysfunction, cardiomyocyte stress, inflammation and coagulation were validated, supporting tissue assessment and therapeutic decision-making.



Diabetes

Novel islet purification method at LUMC

A new purification method for stem cell-derived insulin-producing islets sharply improves product purity and reduces unwanted cell types, strengthening safety and regulatory acceptability.

Delivery device selected, safety testing underway

An open-structure device design was chosen and preclinical safety testing by an external private partner is running, with final reports for the regulatory dossier due in 2026.



Eye

Efficient corneal endothelial cell production

Researchers developed a highly efficient method for producing corneal endothelial cells, including a functional quality control assay for the cells.

Biomaterial membrane moves to the Pilot Factory

Development of the biomaterial membrane progressed, with production transferring to the Smart BioMaterials Center in early 2026 ahead of pre-clinical safety and efficacy work.



Kidney

Functional donor-derived tubuloids on a chip

Donor-derived kidney tubuloids were grown on a chip, replicating human distal tubular function and allowing precise assessment of water and sodium transport and drug and toxin responses.

Route to commercialisation with Mimetas

UMC Utrecht, Mimetas and the Kidney Foundation are advancing this animal-free model towards commercialisation, with regenerative interventions to be integrated from 2026.



Osteoarthritis

Strategic roadmap completed

A strategic roadmap set the phased pathway for a tissue-engineered ATMP for deep osteochondral defects, with the Target Product Profile scheduled for finalisation in 2026.

GMP cartilage cells produced in Flanders

The Flanders team achieved GMP production of primary human articular cartilage cells as building blocks for large osteochondral implants, ahead of cartilage patches in 2026.

Pilot Factory Highlights

State-of-the-art facilities — cleanrooms and pilot lines open to partners

Embedded expertise — technical and regulatory support on site

Scale-up platform — accelerating translation and manufacturing



Smart BioMaterials Center
Eindhoven

The pilot production site on the High Tech Campus was delivered and welcomed its first customer — the step from construction project to operating pilot factory. Four new cleanrooms totalling 400 m² opened for GMP production pipelines.



Innovation Center for Advanced Therapies
Utrecht

ICAT signed a contract with PlusUltra and made further progress on the construction of its new production facility. Alongside the build-out, activity in the innovation lab continued to grow, including a three-day Organ-on-a-Chip masterclass.



ReGEN Biomedical
Maastricht

At the ReGEN test centre a partial proof-of-concept setup was realised for the next generation ('Gen 2') of equipment — an early but concrete step toward the centre's future capabilities. ReGEN also joined the funded NEOLIVER and micro2MACRO consortia.



NecstGen
Leiden


The genetically modified hiPSC toolbox was expanded, and NecstGen supports the GMP transition and scale-up of stem cell-derived insulin-producing cells for the Diabetes Moonshot. It also joined the IPCEI Med4Health consortium on cost-effective production.



LUMC
Leiden

Concrete progress was made on automating the facility at LUMC's iPSC & Organ-on-Chip Hotel, strengthening reproducible cell production for the Moonshot programmes.

International Cooperation in 2025



Funding 2025

The Stichting RegMed XB is mainly funded through partner contribution, provincial funding, and various national government subsidy schemes, including the National Growth Fund.



1 Partner contribution

Three year commitment 2026–2028: Office funding plus co-funding of Moonshots, from academic partners, health foundations and WEWIS Flanders.




2 Provincial funding

Three year commitment 2025–2027.



3 RegMed XB Pilot Factory

Eightyear commitment 2021–2028.
• 1.4 million of the €56.3 million NGF subsidy is for project coordination by the Office.



For patients: affordable regenerative medicine solutions for chronic diseases.
For society: a competitive and sustainable regenerative medicine industry.

Ecosystem overview

These programmes sit outside the Office's stand-alone annual accounts and show the broader resources mobilised across the RegMedXB regenerative medicine ecosystem.



Health Holland PPP programme

Public-private partnerships for health innovation.

€2 million allocated in 2025 for two Moonshot projects:

- Diabetes (INSPIRE)
€1.02 million, 10 partners, 3 years
- Osteoarthritis (SPARC)
€9.8 million, 11 partners, 2 years



TTT Valorisation programme

Translational acceleration and innovation.

- €10 million for new TTT programme 2025-2030 awarded.



RegMed XB's Pilot Factory

National Pilot Factory infrastructure scale-up. Our pilot lines drive manufacturing readiness across the ecosystem, and are involved in the Moonshots.

Office 2025

The Stichting RegMed XB is presented on a stand-alone basis, providing a clearer view of the organisation's own income and costs.

OFFICE BALANCE SHEET

(€ x 1, as of 31 December)

2025

2024

ASSETS

Tangible fixed assets	42.861	53.617
Debtors	103.861	0
Prepayments and accrued income	1.145.220	1.196.614
Subtotal receivables	1.249.081	1.196.614
Cash and banks	1.976.692	1.618.937
Total assets	3.268.634	2.869.168

EQUITY AND LIABILITIES

Unappropriated reserve	244.408	0
Creditors	21.635	64.317
Taxes and social security charges	63.294	47.179
Accruals and deferred income	2.939.297	2.757.673
Subtotal current liabilities	3.024.226	2.869.168
Total equity and liabilities	3.268.634	2.869.168

EXPENSES

2025

2024

Management		431.524	550.313
Project		472.828	426.031
Office		265.981	207.773
Marketing & com.		239.770	208.401
Audit & adm.		212.327	289.607
Governance		78.285	345.141
Total expenses		1.700.715	2.027.266

INCOME

2025

2024


Grant		460.147	405.114
General office/support		1.484.976	1.622.152
Total income		1.945.123	2.027.266

Unappropriated result

€244.408 2024: €0

Governance **Stichting RegMed XB**

In 2025 two councils were established to strengthen the involvement of partners and independent experts in the organisation's direction: the Partner Council, a newly established body bringing together decision-makers from RegMed XB's partner organisations, and the Expert Council, which succeeded the former Scientific Advisory Board to provide scientific and strategic expertise in the further development of regenerative medicine products. Both councils became operational during 2025, alongside the existing Supervisory Board and Management Team.



PARTNER COUNCIL

- Leiden University Medical Centre
- Utrecht University/UMCU Medical Center Utrecht
- Maastricht University/Maastricht UMC+
- Eindhoven University of Technology
- Nierstichting Nederland
- Stichting Reuma Nederland
- De Nederlandse Hartstichting
- Diabetes Fonds
- Oogfonds
- RegMed XB vzw

SUPERVISORY BOARD

- Conny Helder (Chair)
- Koenraad Debackere
- Maurice Horsten
- Arno van Son
- Floris Italianer

EXECUTIVE BOARD & MANAGEMENT TEAM

- Bernard Mulder (CEO)
- Frank Luyten
- Tom Oostrom (non-exec)
- Erik Eijrond
- Bart Geers
- Olaf Geurts

EXPERT COUNCIL

- Nico Stam (Chair)
- Prof. Dr. Philippe Menasché
- Prof. Dr. Katja Schenke-Layland
- Prof. Dr. Thierry Berney
- Prof. Alicia El Haj
- Prof. Dr. Caroline Klaver
- Prof. Dr. Nine Knoers
- Dr. Frans van Andel
- Stef C. Schutte
- Prof. Dr. Maurilio Sampaolesi

Looking ahead



Research Excellence

- €2 million Public-Private Partnerships funding annually through 2027
- Development of five Moonshots



Business Development

- Thematic Tech Transfer (TTT) programme (2025-2030) fully operational
- Expanded scouting capacity



Infrastructure

- New Moonshots in Pilot Factory
- Increased manufacturing readiness



Internationalisation

- European ATMP Centre of Excellence ambition
- More Dutch-Japanese collaboration



Upcoming Events



RegMed XB-DCVA Event

3 November 2026


Joint event to connect, share and accelerate.



Annual Conference

23 – 24 June 2027

Two days of insights, innovation and international collaboration.



Thanks to all

Health Foundations



Pilot Factory pilot lines



Industrial partners



Academic partners



Governmental partners



Life Science & Health partners



Valorisation partners

